M. Trikha, R. Corringham, B. Klein, and J. Rossi, Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence, Clin Cancer Res, vol.9, pp.4653-4665, 2003.
URL : https://hal.archives-ouvertes.fr/inserm-00136067

T. Naka, N. Nishimoto, and T. Kishimoto, The paradigm of IL-6: from basic science to medicine, Arthritis Research, vol.4, issue.Suppl 3, pp.233-242, 2002.
DOI : 10.1186/ar565

L. Alberti, M. Thomachot, T. Bachelot, C. Menetrier-caux, and I. Puisieux, IL-6 as an intracrine growth factor for renal carcinoma cell lines, International Journal of Cancer, vol.23, issue.5, pp.653-661, 2004.
DOI : 10.1002/ijc.20287

B. Klein, X. Zhang, J. M. Content, J. Houssiau, and F. , Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6, Blood, vol.73, pp.517-526, 1989.

H. Preti, F. Cabanillas, M. Talpaz, S. Tucker, and J. Seymour, Prognostic Value of Serum Interleukin-6 in Diffuse Large-cell Lymphoma, Annals of Internal Medicine, vol.127, issue.3, pp.186-194, 1997.
DOI : 10.7326/0003-4819-127-3-199708010-00002

B. Klein, X. Zhang, J. M. Boiron, J. Portier, and M. , Interleukin- 6 is the central tumor growth factor in vitro and in vivo in multiple myeloma, Eur Cytokine Netw, vol.1, pp.193-201, 1990.

T. Bachelot, I. Ray-coquard, C. Menetrier-caux, M. Rastkha, and A. Duc, Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients, British Journal of Cancer, vol.88, issue.11, pp.1721-1726, 2003.
DOI : 10.1038/sj.bjc.6600956

S. Negrier, D. Perol, C. Menetrier-caux, B. Escudier, and M. Pallardy, Interleukin-6, Interleukin-10, and Vascular Endothelial Growth Factor in Metastatic Renal Cell Carcinoma: Prognostic Value of Interleukin-6???From the Groupe Fran??ais d'Immunoth??rapie, Journal of Clinical Oncology, vol.22, issue.12, pp.2371-2378, 2004.
DOI : 10.1200/JCO.2004.06.121

T. Kishimoto, The biology of interleukin-6, Blood, vol.74, pp.1-10, 1989.

P. Heinrich, I. Behrmann, G. Muller-newen, F. Schaper, and L. Graeve, Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway, Biochemical Journal, vol.334, issue.2, pp.297-314, 1998.
DOI : 10.1042/bj3340297

P. Heinrich, I. Behrmann, S. Haan, H. Hermanns, and G. Muller-newen, Principles of interleukin (IL)-6-type cytokine signalling and its regulation, Biochemical Journal, vol.374, issue.1, pp.1-20, 2003.
DOI : 10.1042/bj20030407

D. Krebs and D. Hilton, SOCS Proteins: Negative Regulators of Cytokine Signaling, Stem Cells, vol.273, issue.5, pp.378-387, 2001.
DOI : 10.1634/stemcells.19-5-378

A. Gonzalez-angulo, F. Morales-vasquez, and G. Hortobagyi, Overview of Resistance to Systemic Therapy in Patients with Breast Cancer, Adv Exp Med Biol, vol.608, pp.1-22, 2007.
DOI : 10.1007/978-0-387-74039-3_1

S. Alas, C. Emmanouilides, and B. Bonavida, Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non- Hodgkin's lymphoma to apoptosis, Clin Cancer Res, vol.7, pp.709-723, 2001.

D. Conze, L. Weiss, P. Regen, A. Bhushan, and D. Weaver, Autocrine production of interleukin 6 causes multidrug resistance in breast cancer cells, Cancer Res, vol.61, pp.8851-8858, 2001.

Y. Mizutani, B. Bonavida, Y. Koishihara, K. Akamatsu, and Y. Ohsugi, Sensitization of human renal cell carcinoma cells to cis-diamminedichloroplatinum(II ) by anti-interleukin 6 monoclonal antibody or anti-interleukin 6 receptor monoclonal antibody, Cancer Res, vol.55, pp.590-596, 1995.

N. Voorzanger-rousselot, M. Favrot, and J. Blay, Resistance to cytotoxic chemotherapy induced by CD40 ligand in lymphoma cells, Blood, vol.92, pp.3381-3387, 1998.

J. Lotem and L. Sachs, Differential suppression by protease inhibitors and cytokines of apoptosis induced by wild-type p53 and cytotoxic agents., Proceedings of the National Academy of Sciences, vol.93, issue.22, pp.12507-12512, 1996.
DOI : 10.1073/pnas.93.22.12507

G. Dedoussis, A. Mouzaki, M. Theodoropoulou, P. Menounos, and M. Kyrtsonis, Endogenous Interleukin 6 Conveys Resistance to cis-Diamminedichloroplatinum-Mediated Apoptosis of the K562 Human Leukemic Cell Line, Experimental Cell Research, vol.249, issue.2, pp.269-278, 1999.
DOI : 10.1006/excr.1999.4442

E. Yonish-rouach, D. Resnitzky, J. Lotem, L. Sachs, and A. Kimchi, Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6, Nature, vol.352, issue.6333, pp.345-347, 1991.
DOI : 10.1038/352345a0

D. Otero, V. Poli, M. David, and R. Rickert, Cutting Edge: Inherent and Acquired Resistance to Radiation-Induced Apoptosis in B Cells: A Pivotal Role for STAT3, The Journal of Immunology, vol.177, issue.10, pp.6593-6597, 2006.
DOI : 10.4049/jimmunol.177.10.6593

T. Tamatani, M. Azuma, Y. Ashida, K. Motegi, and R. Takashima, Enhanced radiosensitization and chemosensitization in NF-?B-suppressed human oral cancer cells via the inhibition of ?-irradiation- and 5-FU-induced production of IL-6 and IL-8, International Journal of Cancer, vol.14, issue.6, pp.912-921, 2004.
DOI : 10.1002/ijc.11640

M. Akmansu, D. Unsal, H. Bora, and S. Elbeg, Influence of locoregional radiation treatment on tumor necrosis factor-?? and interleukin-6 in the serum of patients with head and neck cancer, Cytokine, vol.31, issue.1, pp.41-45, 2005.
DOI : 10.1016/j.cyto.2005.02.009

B. Petrini, B. Andersson, O. Strannegard, J. Wasserman, and H. Blomgren, Monocyte release and plasma levels of interleukin-6 in patients irradiated for cancer, In Vivo, vol.6, pp.531-534, 1992.

V. Guillemard and H. Saragovi, Novel Approaches for Targeted Cancer Therapy, Current Cancer Drug Targets, vol.4, issue.4, pp.313-326, 2004.
DOI : 10.2174/1568009043332989

P. Moreau, J. Harousseau, J. Wijdenes, N. Morineau, and N. Milpied, A combination of anti-interleukin 6 murine monoclonal antibody with dexamethasone and high-dose melphalan induces high complete response rates in advanced multiple myeloma, British Journal of Haematology, vol.98, issue.3, pp.661-664, 2000.
DOI : 10.1038/sj.bmt.1701763

N. Shinomiya, Y. Kuno, F. Yamamoto, M. Fukasawa, and A. Okumura, Different mechanisms between premitotic apoptosis and postmitotic apoptosis in X-irradiated U937 cells, International Journal of Radiation Oncology*Biology*Physics, vol.47, issue.3, pp.767-777, 2000.
DOI : 10.1016/S0360-3016(99)00517-9

Z. Zhou, Q. Shi, J. Wang, Y. Chen, and Y. Zhuang, Sensitization of multiple myeloma and B lymphoma lines to dexamethasone and ?-radiation-induced apoptosis by CD40 activation, Apoptosis, vol.189, issue.Suppl 1, pp.123-134, 2005.
DOI : 10.1007/s10495-005-6067-6

B. Cummings, G. Kinsey, L. Bolchoz, and R. Schnellmann, Identification of Caspase-Independent Apoptosis in Epithelial and Cancer Cells, Journal of Pharmacology and Experimental Therapeutics, vol.310, issue.1, pp.126-134, 2004.
DOI : 10.1124/jpet.104.065862

M. Razandi, A. Pedram, and E. Levin, Plasma Membrane Estrogen Receptors Signal to Antiapoptosis in Breast Cancer, Molecular Endocrinology, vol.14, issue.9, pp.1434-1447, 2000.
DOI : 10.1210/mend.14.9.0526

B. Turner, U. Rapp, H. App, M. Greene, and K. Dobashi, Interleukin 2 induces tyrosine phosphorylation and activation of p72-74 Raf-1 kinase in a T-cell line., Proceedings of the National Academy of Sciences, vol.88, issue.4, pp.1227-1231, 1991.
DOI : 10.1073/pnas.88.4.1227

J. Johnston, C. Bacon, D. Finbloom, R. Rees, and D. Kaplan, Tyrosine phosphorylation and activation of STAT5, STAT3, and Janus kinases by interleukins 2 and 15., Proceedings of the National Academy of Sciences, vol.92, issue.19, pp.8705-8709, 1995.
DOI : 10.1073/pnas.92.19.8705

U. Sommer, C. Schmid, R. Sobota, U. Lehmann, and N. Stevenson, Mechanisms of SOCS3 Phosphorylation upon Interleukin-6 Stimulation: CONTRIBUTIONS OF Src- AND RECEPTOR-TYROSINE KINASES, Journal of Biological Chemistry, vol.280, issue.36, pp.31478-31488, 2005.
DOI : 10.1074/jbc.M506008200

S. Alas and B. Bonavida, Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs, Cancer Res, vol.61, pp.5137-5144, 2001.

Y. Mizutani, B. Bonavida, Y. Nio, and O. Yoshida, Overcoming TNF-alpha and drug resistance of human renal cell carcinoma cells by treatment with pentoxifylline in combination with TNF-alpha or drugs: the role of TNF-alpha mRNA downregulation in tumor cell sensitization, J Urol, vol.151, pp.1697-1702, 1994.

M. Jourdan, K. Tarte, E. Legouffe, J. Brochier, and J. Rossi, Tumor necrosis factor is a survival and proliferation factor for human myeloma cells, Eur Cytokine Netw, vol.10, pp.65-70, 1999.
URL : https://hal.archives-ouvertes.fr/inserm-00142273

N. Voorzanger, R. Touitou, E. Garcia, H. Delecluse, and F. Rousset, Interleukin (IL)-10 and IL-6 are produced in vivo by non-Hodgkin's lymphoma cells and act as cooperative growth factors, Cancer Res, vol.56, pp.5499-5505, 1996.

X. Zhang, J. Blenis, H. Li, C. Schindler, and S. Chen-kiang, Requirement of serine phosphorylation for formation of STAT-promoter complexes, Science, vol.267, issue.5206, pp.1990-1994, 1995.
DOI : 10.1126/science.7701321

C. Lufei, T. Koh, T. Uchida, and X. Cao, Pin1 is required for the Ser727 phosphorylation-dependent Stat3 activity, Oncogene, vol.6, issue.55, pp.7656-7664, 2007.
DOI : 10.1038/sj.onc.1210567

J. Schuringa, H. Schepers, E. Vellenga, and W. Kruijer, Ser727-dependent transcriptional activation by association of p300 with STAT3 upon IL-6 stimulation, FEBS Letters, vol.21, issue.1-2, pp.71-76, 2001.
DOI : 10.1016/S0014-5793(01)02354-7

J. Chung, E. Uchida, T. Grammer, and J. Blenis, STAT3 serine phosphorylation by ERK-dependent and -independent pathways negatively modulates its tyrosine phosphorylation., Molecular and Cellular Biology, vol.17, issue.11, pp.6508-6516, 1997.
DOI : 10.1128/MCB.17.11.6508
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC232504

J. Park, K. Ahn, E. Bae, B. Kim, and B. Kim, Blockage of interleukin-6 signaling with 6-amino-4-quinazoline synergistically induces the inhibitory effect of bortezomib in human U266 cells, Anti-Cancer Drugs, vol.19, issue.8, pp.777-782, 2008.
DOI : 10.1097/CAD.0b013e32830c236a

B. Barut, L. Zon, M. Cochran, S. Paul, and D. Chauhan, Role of interleukin 6 in the growth of myelomaderived cell lines, Leukemia Research, vol.16, issue.10, pp.951-959, 1992.
DOI : 10.1016/0145-2126(92)90073-G

N. Borsellino, A. Belldegrun, and B. Bonavida, Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines, Cancer Res, vol.55, pp.4633-4639, 1995.

C. Visco, T. Vassilakopoulos, K. Kliche, G. Nadali, and S. Viviani, Elevated Serum Levels of IL-10 are Associated with Inferior Progression-Free Survival in Patients with Hodgkin's Disease Treated with Radiotherapy, Leukemia & Lymphoma, vol.190, issue.2, pp.2085-2092, 2004.
DOI : 10.1093/intimm/5.12.1599

M. Cassatella, S. Gasperini, C. Bovolenta, F. Calzetti, and M. Vollebregt, Interleukin-10 (IL-10) selectively enhances CIS3/SOCS3 mRNA expression in human neutrophils: evidence for an IL-10-induced pathway that is independent of STAT protein activation, Blood, vol.94, pp.2880-2889, 1999.

C. Niemand, A. Nimmesgern, S. Haan, P. Fischer, and F. Schaper, Activation of STAT3 by IL-6 and IL-10 in Primary Human Macrophages Is Differentially Modulated by Suppressor of Cytokine Signaling 3, The Journal of Immunology, vol.170, issue.6, pp.3263-3272, 2003.
DOI : 10.4049/jimmunol.170.6.3263